Sign in to view content

Abicipar Phase 2 MAPLE Trial Supports Improved Safety for Patients With nAMD Following a Modified Manufacturing Process

Raj K. Maturi, MD

Video
Published 2019

Raj K. Maturi, MD

Late Breakers Symposium

Related

Abicipar Pegol Phase 3 AMD Studies
Pravin U. Dugel, MD
Updates from the Field
2017
Effect of Adjuvant Topical Dorzolamide-Timolol Versus Placebo in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
Jason Hsu, MD
On Demand Cases, Courses, and Papers
2020
FIDO Study: 10-Year Outcomes of Eyes Receiving Continuous, Fixed-Interval Dosing of Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
Ivan J. Suner, MD, MBA
Annual Meeting Talks
2019

Category: AMD-Neovascular

Neovascualar AMD Clinical Trials

See more